Results 151 to 160 of about 1,730,988 (338)
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Genetics of Style-Length in Oxalis [PDF]
, 1948 Ronald Aylmer Fisher, V. C. MARTIN
openalex +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Utilization of genomic services among physicians in Kenya. [PDF]
PLoS OneSigilai H, Ogola E, Ilovi S.
europepmc +1 more source
Genetics of diabetes and its complications: a comprehensive review [PDF]
Abdul Sami +5 more
openalex +1 more source
New Concepts in Plant Breeding and Genetics [PDF]
, 2017 Venkata Ravi Prakash Reddy
openalex +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Correction: Achieving the vision of genomics to improve health for all requires a focus on diversity, equity and inclusion. [PDF]
J Community GenetKhoury MJ, McBride CM, Cornel MC.
europepmc +1 more source